Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities.

Nat Commun · 2018 · PMC6303322 · PMID 30575746

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

As with the vemurafenib secondary pool, we calculated a validation rate based on an empirical FDR threshold of <5% and observed a clear trend in the validation rates of genes in the secondary screen based on their performance in the primary screen (Fig. 6e ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.